Form 4: Edwards Lifesciences CEO Bernard Zovighian Executes Stock Sale Under 10b5-1 Plan
SEC Form 4 Filing
CEO Bernard Zovighian sold 8,617 shares of Edwards Lifesciences Corp. common stock at $87.68 per share on May 30, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 30, 2024, Bernard J. Zovighian, CEO of Edwards Lifesciences Corp, sold 8,617 shares of common stock at a price of $87.68 per share.
- The transaction was executed under a Rule 10b5-1 trading plan adopted on February 29, 2024.
- Following the transaction, Zovighian directly owns 68,217.9005 shares and indirectly owns 3,267.6552 shares through a 401(k).
- Linda J. Park, Attorney-in-Fact, signed the Form 4 on behalf of Bernard J. Zovighian.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock sale by the CEO. It doesn't inherently convey positive or negative sentiment.
Positives
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it was planned in advance and not based on immediate market information.
Industry Context
Executive stock sales are common and often pre-planned, especially in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.
Stakeholder Impact
- The stock sale could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
Key Dates
| Date | Description |
|---|---|
| 02/29/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person |
| 05/30/2024 | Date of the stock sale transaction |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.